Form 4: REGENXBIO CFO Mitchell Chan Receives Equity Awards

REGENXBIO Inc.'s Chief Financial Officer, Mitchell Chan, was granted 73,749 shares of common stock through restricted stock units and 39,650 stock options on January 6, 2026.

Summary

• Mitchell Chan, Chief Financial Officer of REGENXBIO Inc., acquired 73,749 shares of common stock on January 6, 2026, through a time-based restricted stock unit (RSU) award.
• The RSU award vests 25% annually on January 6, 2027, January 6, 2028, January 6, 2029, and January 6, 2030, contingent on continuous service.
• Additionally, Mr. Chan acquired 39,650 stock options with an exercise price of $14.18 per share on January 6, 2026.
• The stock options vest 25% after 12 months of continuous service (January 6, 2027), with the remaining balance vesting in equal monthly installments over the subsequent 36 months, also contingent on continuous service.
• Following these transactions, Mr. Chan beneficially owns 127,717 shares of common stock and 39,650 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of equity awards to a key executive like the CFO is generally viewed positively as it aligns management's interests with long-term shareholder value and serves as a retention incentive. It is a routine compensation event and not indicative of immediate operational or financial performance.

Positives

• The grant of restricted stock units and stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders.
• Equity awards serve as a strong incentive for executive retention and continued service to the company.

Negatives

• The issuance of new equity awards, once vested and exercised, can lead to a degree of share dilution for existing shareholders, though this is a standard practice for executive compensation.

Risks

• The value of the equity awards is subject to the future market price fluctuations of REGENXBIO Inc.'s common stock.
• Vesting of both RSUs and stock options is contingent upon the recipient's continuous service to the Issuer, meaning forfeiture if service terminates before vesting dates.

Future Outlook

The filing outlines future vesting schedules for the granted restricted stock units and stock options, contingent on the Chief Financial Officer's continuous service to REGENXBIO Inc. through January 6, 2030, for RSUs, and through January 6, 2027, with subsequent monthly vesting for options.

Industry Context

The grant of equity awards, such as restricted stock units and stock options, is a standard and widely adopted practice in the biotechnology and pharmaceutical industries for executive compensation. This approach is designed to attract, retain, and motivate key talent by aligning their financial interests with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• The use of time-based restricted stock units (RSUs) and stock options for executive compensation is consistent with common practices observed across the biotechnology sector.
• The multi-year vesting schedules (e.g., 4-year annual vesting for RSUs and 1-year cliff followed by monthly vesting for options) are typical structures aimed at promoting long-term executive retention and performance alignment.
• While specific comparable companies or projects are not detailed in this filing, the general structure of these equity grants aligns with industry benchmarks for executive incentive plans.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of awards, but also benefit from increased alignment of executive interests with long-term company performance.
• Employees: The grant to a key executive may influence overall compensation strategies and morale within the company.

Next Steps

• Vesting of 25% of the RSU shares on January 6, 2027, January 6, 2028, January 6, 2029, and January 6, 2030, subject to continuous service.
• Vesting of 25% of the stock options after 12 months of continuous service (January 6, 2027), with the balance vesting in equal monthly installments over the subsequent 36 months, subject to continuous service.

Key Dates

Keywords

REGENXBIO, RGNX, Mitchell Chan, CFO, Form 4, SEC filing, equity compensation, restricted stock units, RSUs, stock options, insider transaction, executive compensation